Humoral Immunogenicity of mRNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease and Healthy Controls.
Journal
The American journal of gastroenterology
ISSN: 1572-0241
Titre abrégé: Am J Gastroenterol
Pays: United States
ID NLM: 0421030
Informations de publication
Date de publication:
01 01 2022
01 01 2022
Historique:
received:
20
08
2021
accepted:
27
10
2021
pubmed:
20
11
2021
medline:
14
1
2022
entrez:
19
11
2021
Statut:
ppublish
Résumé
Patients with inflammatory bowel disease (IBD) on immune-modifying therapies may have a lower vaccine response to certain vaccines. The aim of our study was to evaluate humoral immunogenicity of mRNA coronavirus disease 2019 (COVID-19) vaccines among patients with IBD and healthy controls (HCs). We performed a prospective study to evaluate humoral immunogenicity among patients with IBD and HCs after completion of mRNA COVID-19 vaccines. One hundred twenty-two patients with IBD and 60 HCs were enrolled. All HCs and 97% of patients with IBD developed antibodies. Antibody concentrations were lower in patients with IBD compared with those in HCs (median 31 vs 118 μg/mL; P < 0.001). Those who received the mRNA-1273 (Moderna) COVID-19 (median 38; interquartile range [IQR] 24-75 vs μg/mL) had higher antibody concentrations compared with those who received the Pfizer-BNT vaccine series (median 22; IQR 11-42 μg/mL; P < 0.001). Patients on immune-modifying therapy (median 26; IQR 13-50 μg/mL) had lower antibody concentrations compared with those who were on no treatment, aminosalicylates, or vedolizumab (median 59; IQR 31-75 μg/mL; P = 0.003). Almost all patients with IBD in our study mounted an antibody response. Future studies are needed in evaluating sustained humoral immunity and the impact of booster dosing in patients with IBD.
Identifiants
pubmed: 34797219
doi: 10.14309/ajg.0000000000001570
pii: 00000434-202201000-00027
doi:
Substances chimiques
Antibodies, Viral
0
2019-nCoV Vaccine mRNA-1273
EPK39PL4R4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
176-179Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 by The American College of Gastroenterology.
Références
Rolak S, Hayney MS, Farraye FA, et al. What gastroenterologists should know about COVID-19 vaccines. Clin Gastroenterol Hepatol 2021;19:657–61.
Caldera F, Hayney MS, Farraye FA. Vaccination in patients with inflammatory bowel disease. Am J Gastroenterol 2020;115:1356–61.
Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 2021;325:2204–6.
Pozdnyakova V, Botwin GJ, Sobhani K, et al. Decreased antibody responses to Ad26.COV2.S relative to SARS-CoV-2 mRNA vaccines in patients with inflammatory bowel disease. Gastroenterology. [Epub ahead of print August 12, 2021.] doi: 10.1053/j.gastro.2021.08.014.
doi: 10.1053/j.gastro.2021.08.014
Kappelman MD, Weaver KN, Boccieri M, et al. Humoral immune response to messenger RNA COVID-19 vaccines among patients with inflammatory bowel disease. Gastroenterology 2021;161:1340–3.
Walsh EE, Frenck RW, Falsey AR, et al. Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. New Engl J Med 2020;383:2439–50.
Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 breakthrough infections in vaccinated health care workers. New Engl J Med 2021;385:1474–84.
Caldera F, Hillman L, Saha S, et al. Immunogenicity of high dose influenza vaccine for patients with inflammatory bowel disease on anti-TNF monotherapy: A randomized clinical trial. Inflamm Bowel Dis 2020;26:593–602.
Self WH, Tenforde MW, Rhoads JP, et al. Comparative effectiveness of Moderna, pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions—United States, March–August 2021. MMWR Morb Mortal Wkly Rep 2021;70:1337–43.
https://www.cdc.gov/media/releases/2021/p0924-booster-recommendations-.html ). Accessed September 27, 2021.
Shrotri M, Navaratnam AMD, Nguyen V, et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet (London, England) 2021;398:385–7.
Krammer F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. Nat Med 2021;27:1147–8.
Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020;383:2427–38.